Stocktoria
Pluri Inc. PLUR
Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2007-12-10
Pluri Inc. financials (annual)
Bars are annual figures from 2017 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0M | $1.3M | $326,000 | $287,000 | $234,000 | — | $23,000 | $54,000 | $50,000 | — |
| Gross profit | $453,000 | $654,000 | $322,000 | $278,000 | $234,000 | — | $23,000 | $52,000 | $48,000 | — |
| R&D expense | $15.1M | $12.9M | $12.4M | $15.7M | $24.6M | $30.5M | $23.1M | $29.9M | $26.4M | $24.0M |
| Operating income | -$24.9M | -$22.2M | -$22.2M | -$27.2M | -$41.6M | -$50.6M | -$29.5M | -$35.5M | -$33.7M | -$28.0M |
| Interest expense | — | — | — | $843,000 | $887,000 | $78,000 | — | — | — | — |
| Income tax | -$25,000 | -$5,000 | — | — | — | — | — | — | — | — |
| Net income | -$23.8M | -$22.6M | -$20.9M | -$28.3M | -$41.2M | -$49.9M | -$29.2M | -$35.3M | -$26.1M | -$27.8M |
| EPS (diluted) | $-2.44 | $-3.56 | $-3.99 | $-6.24 | $-1.28 | $-1.77 | — | — | — | — |
| Operating cash flow | -$19.6M | -$18.2M | -$18.0M | -$22.9M | -$36.5M | -$30.9M | -$26.4M | -$29.5M | -$21.4M | -$21.6M |
| Free cash flow | -$20.2M | -$19.8M | -$18.3M | -$23.1M | -$36.8M | -$31.3M | -$26.6M | -$29.7M | -$21.7M | -$22.0M |
| Cash & equivalents | $3.5M | $5.9M | $6.8M | $5.4M | $9.8M | $31.2M | $8.3M | $4.1M | $8.8M | $4.7M |
| Total assets | $24.9M | $38.7M | $39.5M | $50.8M | $68.1M | $93.5M | $65.5M | $31.3M | $39.0M | $37.5M |
| Shareholders' equity | -$23.0M | -$6.8M | $5.4M | $15.3M | $32.2M | $57.2M | $56.1M | $21.8M | $28.5M | $30.3M |
Growth · year-over-year · Revenue CAGR 53.8%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -24.0% | +309.8% | +13.6% | +22.6% | — | — | -57.4% | +8.0% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-06-30. Facts plus Stocktoria's own computed scores — not investment advice.